Clean Yield Group portfolio

Latest available portfolio: Q2 2026 · Holdings as of · Filed ·
$403MFull value: $403,004,272 · USD · 30 Jun 2026
in Form 13F holdings
See latest portfolio changes

Quarterly portfolio filings

Choose a quarter to see holdings and changes. Newer portfolio dates appear first.

Estimated additions and reductions require qualified adjacent-quarter disclosures and use filing-derived prices. A dash means unavailable; these estimates are not actual trade proceeds or costs.

Quarter Holdings SEC-reported value Est. additions Est. reductions Est. net Top Holdings Form Type Accepted by SEC
Q3 2026 $412,176,523 — — — 13F-HR 28 Oct 2026, 13:51
Q2 2026 394 $403,004,272 — — — AAPL, NVDA, ASML, AVGO, CSCO 13F-HR 05 Aug 2026, 12:31
Q1 2026 384 $355,230,170 — — — AAPL, NVDA, AVGO, ASML, CSCO 13F-HR 14 Apr 2026, 10:28
Q4 2025 408 $360,238,351 — — — AAPL, NVDA, AVGO, ASML, CSCO 13F-HR 26 Jan 2026, 10:55
Q3 2025 416 $353,802,170 — — — AAPL, NVDA, AVGO, AWK, ASML 13F-HR 23 Oct 2025, 11:37
Q2 2025 399 $334,292,426 — — — AAPL, NVDA, AVGO, SFM, AWK 13F-HR 17 Jul 2025, 12:16
Q1 2025 444 $306,929,823 — — — AAPL, SFM, NVDA, AWK, UL 13F-HR 14 Apr 2025, 09:41
Q4 2024 454 $314,392,028 — — — AAPL, SFM, NVDA, AVGO, UL 13F-HR 13 Jan 2025, 14:24
Q3 2024 469 $314,573,669 — — — AAPL, SFM, UL, NVDA, AWK 13F-HR 07 Oct 2024, 11:33
Q2 2024 362 $267,708,058 — — — AAPL, SFM, UL, GSK, AWK 13F-HR 10 Jul 2024, 10:57
Q1 2024 379 $257,055,940 — — — AAPL, GSK, UL, SFM, DOC 13F-HR 29 May 2024, 11:39
Q4 2023 363 $237,411,234 — — — AAPL, UL, GSK, TAK, SFM 13F-HR 24 Jan 2024, 15:15
Q3 2023 374 $221,762,675 — — — AAPL, UL, TAK, GSK, VOD 13F-HR 12 Oct 2023, 14:00
Q2 2023 401 $242,782,830 — — — AAPL, UL, TAK, GSK, VOD 13F-HR 26 Jul 2023, 10:11
Q1 2023 420 $234,753,227 — — — AAPL, UL, TAK, GSK, DOC 13F-HR 26 Apr 2023, 09:50
Q4 2022 452 $232,814,271 — — — AAPL, UL, TAK, GSK, DOC 13F-HR 31 Jan 2023, 15:10
Q3 2022 453 $212,656,000 — — — AAPL, UL, VOD, TAK, DOC 13F-HR 31 Oct 2022, 11:49
Q2 2022 416 $240,300,000 — — — AAPL, GSK, UL, VOD, DOC 13F-HR 18 Jul 2022, 15:47
Q1 2022 466 $279,883,000 — — — AAPL, GSK, GRNB, UL, TU 13F-HR 25 Apr 2022, 15:49
Q4 2021 445 $300,542,000 — — — AAPL, GRNB, GSK, TU, UL 13F-HR 24 Jan 2022, 15:58
Q3 2021 467 $282,495,000 — — — AAPL, GRNB, CNBKA, GSK, UL 13F-HR 27 Oct 2021, 14:18
Q2 2021 454 $269,368,000 — — — AAPL, GRNB, CNBKA, GSK, UL 13F-HR 26 Jul 2021, 16:24
Q1 2021 147 $242,060,000 — — — AAPL, CNBKA, VOD, VMBS, UL 13F-HR 26 Apr 2021, 14:10
Q4 2020 418 $236,666,000 — — — AAPL, HASI, UL, TU, CNBKA 13F-HR 26 Jan 2021, 11:04
Q3 2020 368 $201,879,000 — — — AAPL, UN, HASI, VOD, TU 13F-HR 16 Oct 2020, 10:41

Showing 1-25 of 52 filings.

Manager details and filing context
Latest 13F filing
Q2 2026 - 05 Aug 2026
Latest reported 13F value
$403,004,272
Largest 13F holdings
AAPL NVDA ASML AVGO CSCO ANET GSK AWK PLD HASI FERG UL
+8 moreCAC IBM CRM DGX PANW NOK HUBB ECL
Manager location
Norwich, VT
Holdings Value
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .